Table 1.

Completed and ongoing gene therapy clinical trials for nAMD

Trial registration number	Expressed gene	Vector	Phase	Route of delivery	Status	Sponsor	Location	Patients (n)
NCT00109499	PEDF	AAV5	I	Intravitreal	Completed	GenVec	USA	28
NCT01494805	sFLT01	AAV2	I/II	Subretinal	Completed	Lions Eye Institute, Adverum Biotechnologies	Australia	40
NCT03748784	Aflibercept	AAV2	I	Intravitreal	Ongoing	Adverum Biotechnologies	USA	30
NCT01024998	sFLT01	AAV2	I	Intravitreal	Completed	Sanofi Genzyme	USA	19
NCT03066258	Anti-VEGF Fab	AAV8	I/IIa	Subretinal	Ongoing	Regenxbio	USA	42
NCT01301443	Endostatin and angiostatin	EIAV	I	Subretinal	Completed	Oxford BioMedica	USA	21
NCT03585556	sCD59	AAV2	I	Intravitreal	Ongoing	Hemera Biosciences	USA	25

AAV, adeno-associated viral vector; EIAV, equine infectious anaemia lentiviral vector; nAMD, neovascular age-related macular degeneration.